RS
Rene Sindlev
Director10% Owner

Rene Sindlev insider trades: Enochian Biosciences (ENOB) stock purchases

Director, Enochian Biosciences Last trade May 18, 2022 27 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2018
3
Companies
last trade 2022

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Rene reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 18, 2022ENOB↑ Buy$1.0M
May 18, 2022ENOB↑ Buy$1.0M
Jun 4, 2019ENOB↑ Buy$211K
Jun 3, 2019ENOB↑ Buy$268K
May 29, 2019ENOB↑ Buy$132K
May 28, 2019ENOB↑ Buy$239K
May 24, 2019ENOB↑ Buy$31K
May 22, 2019ENOB↑ Buy$3K
May 21, 2019ENOB↑ Buy$115K
Dec 27, 2018ENOB↑ Buy$744K
May 21, 2018ENOB↑ Buy$7K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Rene Sindlev's insider trades

Rene Sindlev is a director at Enochian Biosciences (ENOB). Since May 21, 2018, Rene has reported 11 open-market purchases worth $3.8M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (10 filings), option exercises (4 filings), other transactions (3 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ENOB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.